Five hospitals in England and Wales have switched to urine test, rather than invasive hospital procedure ...
Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...
Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the cancer benefit from immunotherapy with atezolizumab compared to placebo whereas ...
The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer ...
Cellens, a Boston, MA-based cancer diagnostics startup, has raised a $6.5 million seed round. The company is developing a mechanobiology and AI-driven platform, BioFeel, for non-invasive cancer ...
Fox Chase Cancer Center researchers reported positive results from the trial, known as RETAIN-2, demonstrating that a response-adapted bladder-preservation approach involving neoadjuvant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results